US Generics Set for Stupendous Growth

According to our latest report “Booming US Generic Drug Market”, generic drug market in the US has witnessed fast momentum in the past few years on the back of patent expiration of various branded drugs. The share of generic drug in overall prescription sales also experienced tremendous growth both in volume and value terms. Moreover, with the increase in generic prescription and patent expiration of blockbuster drugs, the generic drug market in the US is expected to witness a CAGR of 10% during FY 2010 – FY 2013.

The ongoing research provides intensive details about the generic market’s future prospects and growth drivers. The report also covers key therapeutic segments to analyze the growth potential in generic drug market. It has been found that segments like Human Insulin, Proton Pump Inhibitors, and Erythropoietin provide huge opportunities for the generic market players to introduce generic versions of drugs in near future. Key market growth catalysts are also discussed in the report, which are expected to drive the future growth of the industry.

Besides, extensive research is done on the competitive landscape to enable clients understand growth prospects and future potential. Forecast in this research report has been made considering the possible post-recession impact on the industry. Thus, it provides valuable information to pharmaceutical & generics companies and investors planning to enter this market.

“Booming US Generic Drug Market” also covers government initiatives taken in recent past to enhance generic drug market in the country. It has been found that, the United States government is adopting several measures to support the generic industry. With comparatively low price and standardize quality, generic drug market is forecasted to surge at fast momentum in near future. The report thoroughly examines the current market trends; industrial developments and competitive landscape to enable clients understand the market structure and its progress in coming years.

For more information visit: http://www.rncos.com/Report/IM589.htm